围产期动脉缺血性卒中婴儿强化康复I-ACQUIRE三期试验方案
I-ACQUIRE三期试验为15中心随机对照研究,纳入8至36月龄围产期动脉缺血性卒中伴偏瘫患儿,比较高强度与中强度I-ACQUIRE干预及常规治疗。共招募216例,198例完成基线评估,168例纳入改良意向性分析样本。研究采用盲法评估,主要结局为Emerging Behaviors Scale增益≥7分的比例。
要点
- I-ACQUIRE干预包含约束诱导运动疗法关键组分,由治疗师实施。
- 高剂量为每次6小时、每周5天、共4周;中剂量为每次3小时、每周5天、共4周。
- 主要结局为患侧上肢单手技能Emerging Behaviors Scale增益≥7分的比例。
核心结论
- 若I-ACQUIRE任一剂量带来显著改善,将为婴幼儿康复决策提供三期证据。
- 试验设定了较高的疗效阈值,并计划进行敏感性和探索性分析以考虑不同治疗反应模式。
研究设计与样本
- I-ACQUIRE三期试验为15中心随机临床试验,比较两种剂量I-ACQUIRE与常规治疗。
- 招募8至36月龄、家长报告围产期动脉缺血性卒中、偏瘫、健康良好且未接受过肉毒毒素或约束诱导运动疗法的儿童。
- 中心1:1:1随机分配至高剂量、中剂量或常规治疗组。
- 共招募216例,198例完成基线评估,168例(85男、83女)符合改良意向性分析样本。
- 平均年龄18.0月(SD=7.6)。
主要发现
- 改良意向性分析样本中70%为右侧偏瘫,51%有癫痫发作或癫痫。
- 儿童功能分类级别和家长评分差异较大。
- 研究方案描述了干预组分及治疗保真度的培训与监测。
关键数值与推荐
- 主要结局为Emerging Behaviors Scale患侧上肢单手技能增益≥7分的比例。
- 次要结局为Mini-Assisting Hand Assessment评估双手活动。
- 高剂量I-ACQUIRE为每次6小时、每周5天、共4周;中剂量为每次3小时、每周5天、共4周。
- 统计方法包括两组二项检验和线性混合回归模型。
临床怎么用
- 该方案为围产期动脉缺血性卒中婴幼儿的强化康复提供了可参考的干预剂量与评估框架。
- 临床可关注患侧上肢单手技能和双手活动的标准化评估,并纳入家长对运动技能、治疗反应和压力的评价。
局限性
- 本文为试验方案,尚未报告疗效结果。
- 改良意向性分析样本168例,低于招募的216例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infants and toddlers with perinatal arterial ischemic stroke face a high risk for lifelong neuromotor impairments and multiple disabilities. Phase 3 clinical trial evidence is urgently needed to identify efficacious treatment to improve outcomes. METHODS: The I-ACQUIRE Phase 3 trial (Perinatal Arterial Stroke: A Multisite RCT of Intensive Infant Rehabilitation) is a 15-site randomized clinical trial of 2 dosages of I-ACQUIRE, a multicomponent, therapist-delivered intervention including key components of constraint-induced movement therapy compared with usual and customary treatment. The trial recruited children 8 to 36 months old with parent-reported perinatal arterial ischemic stroke, hemiparesis, good health, and no prior botulinum toxin or constraint-induced movement therapy. Central 1:1:1 randomization assigned children to High-dose I-ACQUIRE (6-hour sessions, 5 days/wk, 4 weeks), Moderate-dose I-ACQUIRE (3-hour sessions, 5 days/wk, 4 weeks), and Usual and Customary Treatment. Blinded assessments at baseline, end-of-treatment, and 6-months later include the Emerging Behaviors Scale (success defined as % with gains ≥7 points), the primary outcome for unilateral skills on the paretic arm-and-hand; and the Mini-Assisting Hand Assessment, the secondary outcome for bimanual activities. Parents also rate children's motor skills, treatment responses, and stress. Statistical analyses include 2-sample binomial tests for group differences and linear mixed regression models. The registered trial adheres to international trial reporting guidelines and has a parent council. RESULTS: This study protocol describes intervention components plus training and monitoring of treatment fidelity. The trial recruited N=216 children; 198 completed baseline assessments, and 168 (85 boys and 83 girls) qualified for the modified intent-to-treat sample. The mean age was 18.0 (SD=7.6) months. A majority had right-sided paresis (70%); 51% had seizures/epilepsy. Children varied widely in functional classification levels and parent ratings. CONCLUSIONS: The trial sets a unique high threshold for efficacy and proposes sensitivity and exploratory analyses to consider differential response patterns to treatment. If 1 or both I-ACQUIRE dosages lead to significant improvements, then Phase 3 evidence will assist in infant/toddler rehabilitation decision-making. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03910075.
引用
- Ramey SL, Lo WD, DeLuca SC, et al. Perinatal Arterial Ischemic Stroke Phase 3 Trial Protocol for Intensive Infant-Toddler Rehabilitation (I-ACQUIRE). Stroke. 2026. PMID: 41649967. doi:10.1161/STROKEAHA.125.053375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。